A Study of Human Multi-Sensory Integration (MSI)

University of Pennsylvania

Status and phase

Suspended

Phase 2

Conditions

Anesthesia Awareness

Treatments

Drug: Propofol

Drug: Ketamine Injectable Product

Study type

Interventional

Funder types

Other

Identifiers

NCT03498391

829800

Details and patient eligibility

About

The primary aim of this study is to determine whether spatiotemporal characteristics of multisensory evoked potentials can be used as a marker of consciousness (awareness) under anesthesia.

The secondary aim is to characterize changes in the characteristics of evoked potentials under anesthesia in both single sensory modality (visual, auditory) and across sensory modalities.

Full description

This is a prospective, dual parallel arm human subject study aimed at determining the relationship between level of sedation (consciousness) and features of multi and uni-sensory evoked potentials with the ultimate goal of developing novel means of detecting consciousness under anesthesia with potential for application to other clinical settings such as brain injury. For this purpose, the investigators have chosen two anesthetics with fundamentally distinct mechanisms of action: propofol and ketamine.

The study will involve healthy compensated volunteers. On the day of the study, an EEG cap will be applied to the participant for monitoring brain activity and an intravenous line will be placed for drug administration. Blood pressure, ECG, pulse oxymetry, and end-tidal carbon dioxide (from nasal cannula) will be monitored. Supplemental oxygen will be administered using a nasal cannula. Subjects will then perform the behavioral tasks in the awake state for approximately 1 hour.

After this phase is complete, participants will receive either propofol or ketamine (chosen permuted block randomization) using a clinician bolus/infusion strategy titrated to Richmond Agitation-Sedation Scale score of -1 (see above). Once the desired sedation level is achieved, subjects will once again complete the behavioral tasks. After the completion of this phase (approximately 1 hour) the anesthetic dose will be increased to attain Richmond Agitation-Sedation Scale -3 to -4. At this level of sedation subjects will not be able to do the behavioral task and only the evoked potentials will be recorded. Upon completion of this phase (approximately 1 hour), sedation level will be decreased to return the subject to a Richmond Agitation-Sedation Scale of -1 and once again the tasks will be repeated.

Finally, the anesthetic infusion will be stopped. Once the Richmond Agitation-Sedation Scale score of 0 is attained, participants will once again perform the behavioral task (approximately 1 hour). This will conclude the experimental phase of the trial. Subjects will be monitored until clinically established discharge criteria are met. This includes adequate respiration, blood pressure, oxygen saturation and activity level. No formal follow-up is required; however, subjects will be called 24 hours after study completion.

Enrollment

40 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy volunteers ages 18-65 years old
American Society of Anesthesiologists (ASA) Physical Status I or II (i.e. healthy)
Body Mass Index <30 kg/m2
Easily visible uvula

Exclusion criteria

Contraindications to administration of either propofol or ketamine
Allergy to either one of the medications or preservative in which it is diluted.
History (or current) seizure disorder
Contraindications to anesthesia
Significant cardiovascular disease (e.g. h/o hypertension, arrhythmias, myocardial infarction, congestive heart failure, congenital heart defects, coronary artery disease)
Increased risk factors for difficult intubation and/or ventilation
Obesity (BMI>=30 kg/m2)
Mallampati class > 2.
History of or current obstructive sleep apnea.
Increased risk of aspiration
Any per oral intake within 8 hours of anesthetic exposure
Conditions that delay gastric emptying (e.g. obesity, hiatal hernia, gastro esophageal reflux disease, pregnancy, etc.)
Pulmonary disease (e.g. chronic obstructive pulmonary disorder, asthma requiring rescue inhaler within last month, emphysema, pulmonary hypertension, pulmonary fibrosis etc).
- Neurological disease. Patients with history of strokes, seizures, brain surgery, brain tumor, increased intracranial pressure.
- Psychiatric disease. History of or presents of psychosis, schizophrenia, schizo-affective disorder.
- Specific Medication Current Use. History of or current intake of antipsychotics or sedatives.
- Drug abuse. History of or current use of illegal drugs such as stimulants or depressants.
- Pregnancy or breastfeeding
- Inability to provide informed consent